Novartis’ cancer combination Tafinlar and Mekinist has been approved by the EMA for adjuvant treatment of advanced melanoma in order to prevent disease recurrence. The new indication – the third for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback